You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine

Article metrics

Article menu

Download PDFPDF

Poster Presentation
Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine

 

Online download statistics by month:

Online download statistics by month: January 2020 to April 2025

AbstractFullPdf
Jan 2020020
Feb 2020023
Mar 2020001
May 2020001
Jun 20200111
Jul 2020022
Aug 2020060
Sep 2020040
Oct 2020002
Nov 2020030
Dec 2020023
Jan 2021050
Feb 2021022
Apr 2021022
May 2021010
Jun 2021001
Jul 2021022
Sep 2021024
Oct 20210317
Nov 20210314
Dec 2021050
Jan 2022033
Feb 2022011
Mar 2022010
Apr 2022022
May 2022066
Jun 2022023
Jul 2022022
Aug 2022031
Sep 2022055
Oct 2022014
Nov 2022031
Dec 2022040
Jan 2023013
Feb 2023010
Mar 2023030
Apr 2023010
May 2023013
Jul 2023015
Aug 2023001
Sep 2023020
Oct 2023031
Nov 2023031
Dec 2023051
Jan 2024051
Feb 2024071
Mar 20240318
Apr 2024030
May 2024066
Jun 2024083
Jul 2024060
Aug 2024070
Sep 2024055
Oct 2024062
Nov 2024062
Dec 2024010
Jan 2025055
Feb 2025020
Mar 20250110
Apr 2025011
Total0183152